Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-30T06:45:01.659Z Has data issue: false hasContentIssue false

Chapter 12 - VPA, lithium, amiodarone, and other non-DA

Published online by Cambridge University Press:  05 July 2015

By
Michael R. Silver  and
Stewart A. Factor
Edited by
Joseph H. Friedman
Joseph H. Friedman
Affiliation:
Department of Neurology, Brown University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Medication-Induced Movement Disorders , pp. 131 - 140
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Esper, CD, Factor, SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord. 2008;23(3):401–4.CrossRefGoogle ScholarPubMed
Bondon-Guitton, E, Perez-Lloret, S, Bagheri, H, Brefel, C, Rascol, O, Montastruc, JL. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26(12):2226–31.CrossRefGoogle Scholar
Remblier, C, Kassir, A, Richard, D, Perault, MC, Guibert, S. [Parkinson syndrome from diltiazem]. Therapie. 2001;56(1):57–9.Google ScholarPubMed
Dick, RS, Barold, SS. Diltiazem-induced parkinsonism. Am J Med. 1989;87(1):95–6.CrossRefGoogle ScholarPubMed
Padrell, MD, Navarro, M, Faura, CC, Horga, JF. Verapamil-induced parkinsonism. Am J Med. 1995;99(4):436.CrossRefGoogle ScholarPubMed
Garcia-Albea, E, Jimenez-Jimenez, FJ, Ayuso-Peralta, L, Cabrera-Valdivia, F, Vaquero, A, Tejeiro, J. Parkinsonism unmasked by verapamil. Clin Neuropharmacol. 1993;16(3):263–5.CrossRefGoogle ScholarPubMed
Garcia-Ruiz, PJ, Javier Jimenez-Jimenez, F, Garcia de Yebenes J. Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson’s disease. Parkinsonism Relat Disord. 1998;4(4):211–4.CrossRefGoogle ScholarPubMed
Teive, HA, Troiano, AR, Germiniani, FM, Werneck, LC. Flunarizine- and cinnarizine-induced parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord. 2004;10(4):243–5.CrossRefGoogle ScholarPubMed
Micheli, FE, Pardal, MM, Giannaula, R, Gatto, M, Parera, I, Paradiso, G, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord. 1989;4(2):139–46.CrossRefGoogle ScholarPubMed
Negrotti, A, Calzetti, S. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord. 1997;12(1):107–10.CrossRefGoogle ScholarPubMed
Marti-Masso, JF, Poza, JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord. 1998;13(3):453–6.CrossRefGoogle ScholarPubMed
Takada, M, Kono, T, Kitai, ST. Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons. Brain Res. 1992; 590 (1–2): 311–5.CrossRefGoogle ScholarPubMed
Sempere, AP, Duarte, J, Cabezas, C, Coria, F, Claveria, LE. Parkinsonism induced by amlodipine. Mov Disord. 1995;10(1):115–6.CrossRefGoogle ScholarPubMed
Teive, HA, Germiniani, FM, Werneck, LC. Parkinsonian syndrome induced by amlodipine: case report. Mov Disord. 2002;17(4):833–5.CrossRefGoogle ScholarPubMed
Nakashima, K, Shimoda, M, Kuno, N, Takahashi, K. Temporary symptom worsening caused by manidipine hydrochloride in two patients with Parkinson’s disease. Mov Disord. 1994;9(1):106–7.CrossRefGoogle ScholarPubMed
Sandyk, R. Parkinsonism induced by captopril. Clin Neuropharmacol. 1985;8(2):197–8.CrossRefGoogle ScholarPubMed
Shimoda, K, Hikasa, C, Nishikawa, S, Takahashi, K. [A case report of captopril-induced parkinsonism]. Rinsho Shinkeigaku. 1987;27(3):366–8.Google ScholarPubMed
Chang, YP, Shih, PY. A case of Parkinson’s disease worsened by captopril: an unexpected adverse effect. Mov Disord. 2009;24(5):790.CrossRefGoogle ScholarPubMed
Hilleman, D, Miller, MA, Parker, R, Doering, P, Pieper, JA. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy. 1998; 18(6 Pt 2): 138S–45S.CrossRefGoogle ScholarPubMed
Charness, ME, Morady, F, Scheinman, MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology. 1984;34(5):669–71.CrossRefGoogle ScholarPubMed
Werner, EG, Olanow, CW. Parkinsonism and amiodarone therapy. Ann Neurol. 1989;25(6):630–2.CrossRefGoogle ScholarPubMed
Berg, A, Bellander, BM, Wanecek, M, Gamrin, L, Elving, A, Rooyackers, O, et al. Intravenous glutamine supplementation to head trauma patients leaves cerebral glutamate concentration unaffected. Intensive Care Med. 2006;32(11):1741–6.CrossRefGoogle ScholarPubMed
Malaterre, HR, Renou, C, Kallee, K, Gauthier, A. Akinesia and amiodarone therapy. Int J Cardiol. 1997;59(1):107–8.CrossRefGoogle ScholarPubMed
Marti Masso, JF, Carrera, N, Urtasun, M. Drug-induced parkinsonism: a growing list. Mov Disord. 1993;8(1):125.Google ScholarPubMed
Matsui, A, Matsuo, H, Takanaga, H, Sasaki, S, Maeda, M, Sawada, Y. Prediction of catalepsies induced by amiodarone, aprindine and procaine: similarity in conformation of diethylaminoethyl side chain. J Pharmacol Exp Ther. 1998;287(2):725–32.Google ScholarPubMed
Dotti, MT, Federico, A. Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov Disord. 1995;10(2):233–4.CrossRefGoogle ScholarPubMed
Lemaire, JF, Autret, A, Biziere, K, Romet-Lemone, JL, Gray, F. Amiodaron neuropathy: further arguments for human drug-induced neurolipidosis. Eur Neurol. 1982;21(1):65–8.CrossRefGoogle ScholarPubMed
Ishida, S, Sugino, M, Hosokawa, T, Sato, T, Furutama, D, Fukuda, A, et al. Amiodarone-induced liver cirrhosis and parkinsonism: a case report. Clin Neuropathol. 2010;29(2):84–8.CrossRefGoogle ScholarPubMed
Masmoudi, K, Masson, H, Gras, V, Andrejak, M. Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases. Fundam Clin Pharmacol. 2012;26(2):198–203.CrossRefGoogle ScholarPubMed
Marti Masso, JF, Marti, I, Carrera, N, Poza, JJ, Lopez de Munain, A. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie. 2005;60(4):419–22.Google Scholar
Papazian, O, Canizales, E, Alfonso, I, Archila, R, Duchowny, M, Aicardi, J. Reversible dementia and apparent brain atrophy during valproate therapy. Ann Neurol. 1995;38(4):687–91.CrossRefGoogle ScholarPubMed
Guerrini, R, Belmonte, A, Canapicchi, R, Casalini, C, Perucca, E. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia. 1998;39(1):27–32.CrossRefGoogle ScholarPubMed
Galimberti, CA, Diegoli, M, Sartori, I, Uggetti, C, Brega, A, Tartara, A, et al. Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation. Neurology. 2006;67(9):1715–7.CrossRefGoogle ScholarPubMed
McLachlan, RS. Pseudoatrophy of the brain with valproic acid monotherapy. Can J Neurol Sci. 1987;14(3):294–6.CrossRefGoogle ScholarPubMed
Straussberg, R, Kivity, S, Weitz, R, Harel, L, Gadoth, N. Reversible cortical atrophy and cognitive decline induced by valproic acid. Eur J Paediatr Neurol. 1998;2(4):213–8.CrossRefGoogle ScholarPubMed
Yamanouchi, H, Ota, T, Imataka, G, Nakagawa, E, Eguchi, M. Reversible altered consciousness with brain atrophy caused by valproic acid. Pediatr Neurol. 2003;28(5):382–4.CrossRefGoogle ScholarPubMed
Mahmoud, F, Tampi, RR. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. Am J Geriatr Pharmacother. 2011;9(6):405–12.CrossRefGoogle ScholarPubMed
Perucca, E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695–714.CrossRefGoogle ScholarPubMed
Zadikoff, C, Munhoz, RP, Asante, AN, Politzer, N, Wennberg, R, Carlen, P, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry. 2007;78(2):147–51.CrossRefGoogle ScholarPubMed
van der Zwan, A Jr. [Transient Parkinson syndrome and tremor caused by the use of sodium valproate]. Ned Tijdschr Geneeskd. 1989;133(24):1230–2.Google ScholarPubMed
Easterford, K, Clough, P, Kellett, M, Fallon, K, Duncan, S. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology. 2004;62(8):1435–7.CrossRefGoogle ScholarPubMed
Jamora, D, Lim, SH, Pan, A, Tan, L, Tan, EK. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord. 2007;22(1):130–3.CrossRefGoogle ScholarPubMed
Ristic, AJ, Vojvodic, N, Jankovic, S, Sindelic, A, Sokic, D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia. 2006;47(12):2183–5.CrossRefGoogle ScholarPubMed
Silver, M, Factor, SA. Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. Parkinsonism Relat Disord. 2013;19(8):758–60.CrossRefGoogle ScholarPubMed
Onofrj, M, Thomas, A, Paci, C. Reversible parkinsonism induced by prolonged treatment with valproate. J Neurol. 1998;245(12):794–6.CrossRefGoogle ScholarPubMed
Sasso, E, Delsoldato, S, Negrotti, A, Mancia, D. Reversible valproate-induced extrapyramidal disorders. Epilepsia. 1994;35(2):391–3.CrossRefGoogle ScholarPubMed
Loscher, W, Nau, H. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J Pharmacol Exp Ther. 1983;226(3):845–54.Google ScholarPubMed
Armon, C, Shin, C, Miller, P, Carwile, S, Brown, E, Edinger, JD, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology. 1996;47(3):626–35.CrossRefGoogle ScholarPubMed
Qian, Y, Zheng, Y, Tiffany-Castiglioni, E. Valproate reversibly reduces neurite outgrowth by human SY5Y neuroblastoma cells. Brain Res. 2009;1302:21–33.CrossRefGoogle ScholarPubMed
Goni, M, Jimenez, M, Feijoo, M. Parkinsonism induced by phenytoin. Clin Neuropharmacol. 1985;8(4):383–4.CrossRefGoogle ScholarPubMed
Ertan, S, Ulu, MO, Hanimoglu, H, Tanriverdi, T, Kafadar, AM, Acar, ZU, et al. Phenytoin-induced parkinsonism. Singapore Med J. 2006;47(11):981–3.Google ScholarPubMed
Factor, S. Lithium-induced movement disorders. In: Sethi, K, editor. Drug-Induced Movement Disorders. New York: Marcel Dekker, Inc.; 2004. p. 209–31.Google Scholar
Baek, JH, Kinrys, G, Nierenberg, AA. Lithium tremor revisited: pathophysiology and treatment. Acta Psychiatr Scand. 2014;129(1):17–23.CrossRefGoogle ScholarPubMed
Vestergaard, P. Clinically important side effects of long-term lithium treatment: a review. Acta Psychiatr Scand Suppl. 1983;305:1–36.Google ScholarPubMed
Branchey, MH, Charles, J, Simpson, GM. Extrapyramidal side effects in lithium maintenance therapy. Am J Psychiatry. 1976;133(4):444–5.Google ScholarPubMed
Shopsin, B, Gershon, S. Cogwheel rigidity related to lithium maintenance. Am J Psychiatry. 1975;132(5):536–8.Google ScholarPubMed
Kane, J, Rifkin, A, Quitkin, F, Klein, DF. Extrapyramidal side effects with lithium treatment. Am J Psychiatry. 1978;135(7):851–3.Google ScholarPubMed
Asnis, GM, Asnis, D, Dunner, DL, Fieve, RR. Cogwheel rigidity during chronic lithium therapy. Am J Psychiatry. 1979;136(9):1225–6.Google ScholarPubMed
Lima, MA, Maradei, S, Maranhao Filho, P. Cyclosporine-induced parkinsonism. J Neurol. 2009;256(4):674–5.CrossRefGoogle ScholarPubMed
Ling, H, Bhidayasiri, R. Reversible Parkinsonism after chronic cyclosporin treatment in renal transplantation. Mov Disord. 2009;24(12):1848–9.CrossRefGoogle ScholarPubMed
Kim, HC, Han, SY, Park, SB, Suh, SJ. Parkinsonism during cyclosporine treatment in renal transplantation. Nephrol Dial Transplant. 2002;17(2):319–21.CrossRefGoogle ScholarPubMed
Wasserstein, PH, Honig, LS. Parkinsonism during cyclosporine treatment. Bone Marrow Transplant. 1996;18(3):649–50.Google ScholarPubMed
Munhoz, RP, Teive, HA, Germiniani, FM, Gerytch, JC Jr., Sa, DS, Bittencourt, MA, et al. Movement disorders secondary to long-term treatment with cyclosporine A. Arq Neuropsiquiatr. 2005;63(3A):592–6.CrossRefGoogle ScholarPubMed
Fisher, JF, Dewald, J. Parkinsonism associated with intraventricular amphotericin B. J Antimicrob Chemother. 1983;12(1):97–9.CrossRefGoogle ScholarPubMed
Mott, SH, Packer, RJ, Vezina, LG, Kapur, S, Dinndorf, PA, Conry, JA, et al. Encephalopathy with parkinsonian features in children following bone marrow transplantations and high-dose amphotericin B. Ann Neurol. 1995;37(6):810–4.CrossRefGoogle ScholarPubMed
Luque, FA, Selhorst, JB, Petruska, P. Parkinsonism induced by high-dose cytosine arabinoside. Mov Disord. 1987;2(3):219–22.CrossRefGoogle ScholarPubMed
Manley, TJ, Chusid, MJ, Rand, SD, Wells, D, Margolis, DA. Reversible parkinsonism in a child after bone marrow transplantation and lipid-based amphotericin B therapy. Pediatr Infect Dis J. 1998;17(5):433–4.CrossRefGoogle Scholar
Chuang, C, Constantino, A, Balmaceda, C, Eidelberg, D, Frucht, SJ. Chemotherapy-induced parkinsonism responsive to levodopa: an underrecognized entity. Mov Disord. 2003;18(3):328–31.CrossRefGoogle ScholarPubMed
Gjerris, F. Transitory procaine-induced Parkinsonism. J Neurol Neurosurg Psychiatry. 1971;34(1):20–2.CrossRefGoogle ScholarPubMed
Matsuo, H, Matsui, A, Nasu, R, Takanaga, H, Inoue, N, Hattori, F, et al. Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice. Pharm Res. 2000;17(5):565–71.CrossRefGoogle Scholar
Sugiyama, Y. [Parkinsonism induced by propiverine hydrochloride–report of 3 cases]. Rinsho Shinkeigaku. 1997;37(10):873–5.Google ScholarPubMed
Neary, D, Thurston, H, Pohl, JE. Development of extrapyramidal symptoms in hypertensive patients treated with diazoxide. Br Med J. 1973;3(5878):474–5.CrossRefGoogle ScholarPubMed
Ott, BR, Lannon, MC. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol. 1992;15(4):322–5.CrossRefGoogle ScholarPubMed
Mintz, U, Liberman, UA, de Vries, A. Parkinsonism syndrome due to cephaloridine. JAMA. 1971;216(7):1200.CrossRefGoogle ScholarPubMed
Parmar, RC, Valvi, CV, Kamat, JR, Vaswani, RK. Chloroquine induced parkinsonism. J Postgrad Med. 2000;46(1):29–30.Google ScholarPubMed
Mizoi, Y, Kaneko, H, Oharazawa, A, Kuroiwa, H. [Parkinsonism in a patient receiving interferon alpha therapy for chronic hepatitis C]. Rinsho Shinkeigaku. 1997;37(1):54–6.Google Scholar
Sarasombath, P, Sumida, K, Kaku, DA. Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia. Hawaii Med J. 2002;61(3):48, 57.Google ScholarPubMed
Lieberman, AN, Goldstein, M. Reversible parkinsonism related to meperidine. N Engl Med J. 1985;312(8):509.Google ScholarPubMed
Olive, JM, Masana, L, Gonzalez, J. Meperidine and reversible parkinsonism. Mov Disord. 1994;9(1):115–6.CrossRefGoogle ScholarPubMed
Kagi, G, Bhatia, KP, Tolosa, E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81(1):5–12.CrossRefGoogle ScholarPubMed
Hambye, AS, Vervaet, A, Dethy, S. FP-CIT SPECT in clinically inconclusive Parkinsonian syndrome during amiodarone treatment: a study with follow-up. Nucl Med Commun. 2010;31(6):583–9.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×